Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System

Abstract

Purpose Complicated skin and soft tissue infections (cSSTI) are associated with high healthcare resource use and costs. The emergency nature of cSSTI hospitalizations requires starting immediate empiric intravenous (IV) antibiotic treatment, making the appropriate choice of initial antibiotic therapy crucial. Patients and Methods The use of ceftaroline fosamil (CFT) as an alternative to other IV antibiotic therapies for the empiric treatment of hospitalized adults with cSSTI (vancomycin, linezolid, daptomycin, cloxacillin, tedizolid) was evaluated through cost consequences analysis. The model structure was a decision tree accounting for four different pathways: patients demonstrating early response (ER) either discharged early (with oral antibiotic) or remaining in hospital to continue the initial therapy; non-responders either remaining on the initial IV therapy or switching to a second-line antibiotic. The model perspective was the Spanish National Health System. Results CFT resulted in average percentage of patients discharged early (PDE) of 24.6% (CI 19.49–30.2%) with average total cost per patient of €6763 (€6268–€7219). Vancomycin, linezolid, daptomycin and tedizolid resulted in average PDE of 22% (17.34–27.09%), 26.4% (20.5–32.32%), 28.6% (22.08–35.79%) and 26.5% (20.39–33.25%), respectively, for a total cost per patient of €6,619 (€5,902–€6,929), €6,394 (€5,881–€6,904), €6,855 (€5,800–€7,410) and €7,173 (€6,608–€7,763), respectively. Key model drivers were ER and antibiotic treatment duration, with hospital costs accounting for over 83% of the total expenditures. Conclusion Given its clinical and safety profile, CFT is an acceptable choice for cSSTI empiric therapy providing comparable ER and costs to other relevant antibiotic options.

Clinical evidence supporting ceftaroline fosamil and ceftobiprole for complicated skin and soft tissue infections

“…A similar economic model was developed to analyze the financial burden of cSSTIs in Spain using the data of the CANVAS 1 and CANVAS 2 studies and data from Spanish Drug Official list. The average total cost per patient treated with ceftaroline was €6763 compared to €6619 with vancomycin, €6394 with linezolid, €6855 with daptomycin and €7173 with tedizolid [29].…”

Nickel Nanoparticles: Applications and Antimicrobial Role against Methicillin-Resistant Staphylococcus aureus Infections

“…Notably, granulocyte counts are also recommended for antibiotics consumption [ 50 , 51 ]. Ceftaroline fosamil has exhibited substantial anti-MRSA effects [ 52 , 53 , 54 ]. Daptomycin and ceftaroline have exhibited higher bactericidal effects and linezolid has exerted strong effects on bacteremia.…”

How to manage skin and soft-tissue infections in the emergency department

“…In patients who started with parenteral therapy, de-escalation to oral treatment is possible when the condition has stabilised, or the etiological agent is known, after 3 to 5 initial days of parenteral treatment, although this criterion is far from precise and should be applied after consultation with a specialist in Infectious Diseases. Levofloxacin, amoxicillin/clavulanic acid, cephalexin, trimethoprim-sulfamethoxazole (TMP-SMX), doxycycline, oxazolidinones, and long-term glycolipopeptides are other potentially useful agents in these circumstances [65 ▪ ].…”